Conflicts between commercial and scientific interests in pharmaceutical advertising for medical journals
- PMID: 14758858
- PMCID: PMC3235690
- DOI: 10.2190/K0JG-EXG1-FB12-0ANF
Conflicts between commercial and scientific interests in pharmaceutical advertising for medical journals
Abstract
In 1992, researchers from the University of California, Los Angeles, published a study on the scientific merit and validity of pharmaceutical advertisements in medical journals. Their results led them to conclude, provocatively, that many pharmaceutical advertisements contained deficiencies in areas in which the U.S. Food and Drug Administration had established explicit standards of quality. This article provides a detailed account of third-party reactions to the study following its publication in the Annals of Internal Medicine, as well as the implications for those involved, including the authors, editors, and publisher. The increasingly diverging interests between medical journal editors and publishers are also discussed and highlighted by two recent cases of editors' departures from prominent general-interest medical journals.
References
-
- Wilkes MS, Doblin BH, Shapiro MF. Pharmaceutical advertisements in leading medical journals: experts’ assessments. Ann. Intern. Med. 1992;116:912–919. - PubMed
-
- Kessler DA. Addressing the problem of misleading advertising. Ann. Intern. Med. 1992;116:950–951. - PubMed
-
- Kunin CM. Blunder drug for pneumonia. N. Engl. J. Med. 1977;297:113–114. - PubMed
-
- Tannock IF. Responsibility in advertising: an oncologist’s view. N. Engl. J. Med. 1979;301:1004. - PubMed
-
- Potter HP., Jr. Costs of drug advertising. N. Engl. J. Med. 1988;319:798. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
